Brolucizumab Emerging Insight And Market Forecast

“BROLUCIZUMAB- Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Diabetic Macular Edema in 7 Major Markets. A detailed picture of the BROLUCIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Beovu (brolucizumab, also known as RTH258) is approved in more than 40 countries, including in the US7, EU8, UK8, Japan9, Canada10 and Australia11, for the treatment of wet AMD. Brolucizumab is the most clinically advanced humanized single-chain antibody fragment (scFv). Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around BROLUCIZUMAB.
  • The report contains forecasted sales for BROLUCIZUMAB till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Diabetic Macular Edema.
  • The report also features the SWOT analysis with analyst insights and key findings of BROLUCIZUMAB.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

BROLUCIZUMAB Analytical Perspective by DelveInsight

  • In-depth BROLUCIZUMAB Market Assessment

This report provides a detailed market assessment of BROLUCIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.


  • BROLUCIZUMAB Clinical Assessment

The report provides the clinical trials information of BROLUCIZUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

  • In the coming years, the market scenario for Diabetic Macular Edema is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
  • The companies and academics are working to assess challenges and seek opportunities that could influence BROLUCIZUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Diabetic Macular Edema are giving market competition to BROLUCIZUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.  
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of BROLUCIZUMAB.
  • Our in-depth analysis of the forecasted sales data of BROLUCIZUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the BROLUCIZUMAB. 

Key Questions

  • Which company is developing BROLUCIZUMAB along with the phase of the clinical study?
  • What is the technology utilized in the development of BROLUCIZUMAB?
  • What is the product type, route of administration and mechanism of action of BROLUCIZUMAB?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the BROLUCIZUMAB development?
  • What are the key designations that have been granted to BROLUCIZUMAB?
  • What is the forecasted market scenario of BROLUCIZUMAB?
  • What is the history of BROLUCIZUMAB and what is its future?
  • What is the forecasted sales of BROLUCIZUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
  • What are the other emerging products available and how these are giving competition to BROLUCIZUMAB?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

 

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assesment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Table

Table 1 BROLUCIZUMAB, Description

Table 2 BROLUCIZUMAB, Clinical Trial Description

Table 3 BROLUCIZUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)

Table 4 Market Competitors

Table 5 Other Emerging Therapies

List of Figures

Figure 1 The Development Timeline of BROLUCIZUMAB

Figure 2 Patent Details, BROLUCIZUMAB

Figure 3 BROLUCIZUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)

Figure 4 BROLUCIZUMAB, US Market Size from 2020 to 2030 (in Millions USD)

Figure 5 BROLUCIZUMAB, EU5 Market Size from 2020 to 2030 (in Millions USD)

Figure 6 BROLUCIZUMAB, Japan Market Size from 2020 to 2030 (in Millions USD)

  • Tags:
  • "BROLUCIZUMAB
  • BROLUCIZUMAB Marketed Drugs Overvi...
  • BROLUCIZUMAB Market Assessment
  • BROLUCIZUMAB API Manufacturers/ Ac...
  • BROLUCIZUMAB US DMF
  • BROLUCIZUMAB US Drug Master Files
  • BROLUCIZUMAB Active Substance Mast...
  • BROLUCIZUMAB Generic players
  • BROLUCIZUMAB Patent Expiration
  • BROLUCIZUMAB Patent Exclusivity
  • BROLUCIZUMAB API Manufacturers
  • BROLUCIZUMAB Global Forecasted Sal...
  • BROLUCIZUMAB API Route of Synthesi...
  • BROLUCIZUMAB Market sales
  • BROLUCIZUMAB SWOT Analysis
  • BROLUCIZUMAB Pipeline "

Forward to Friend

Need A Quote